# Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

> **NCT00038194** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00038194
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038194, "Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00038194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*